Genome-wide association study on the FEV1/FVC ratio in never-smokers identifies HHIP and FAM13A.
van der Plaat, DA
de Jong, K
Lahousse, L
Faiz, A
Vonk, JM
van Diemen, CC
Nedeljkovic, I
Amin, N
Brusselle, GG
Hofman, A
Brandsma, C-A
Bossé, Y
Sin, DD
Nickle, DC
van Duijn, CM
Postma, DS
Boezen, HM
- Publisher:
- Elsevier
- Publication Type:
- Journal Article
- Citation:
- Journal of Allergy and Clinical Immunology, 2017, 139, (2), pp. 533-540
- Issue Date:
- 2017-02
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
1-s2.0-S0091674916308958-main.pdf | 834.16 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | van der Plaat, DA | |
dc.contributor.author | de Jong, K | |
dc.contributor.author | Lahousse, L | |
dc.contributor.author |
Faiz, A |
|
dc.contributor.author | Vonk, JM | |
dc.contributor.author | van Diemen, CC | |
dc.contributor.author | Nedeljkovic, I | |
dc.contributor.author | Amin, N | |
dc.contributor.author | Brusselle, GG | |
dc.contributor.author | Hofman, A | |
dc.contributor.author | Brandsma, C-A | |
dc.contributor.author | Bossé, Y | |
dc.contributor.author | Sin, DD | |
dc.contributor.author | Nickle, DC | |
dc.contributor.author | van Duijn, CM | |
dc.contributor.author | Postma, DS | |
dc.contributor.author | Boezen, HM | |
dc.date.accessioned | 2022-08-15T04:22:11Z | |
dc.date.available | 2016-06-10 | |
dc.date.available | 2022-08-15T04:22:11Z | |
dc.date.issued | 2017-02 | |
dc.identifier.citation | Journal of Allergy and Clinical Immunology, 2017, 139, (2), pp. 533-540 | |
dc.identifier.issn | 0091-6749 | |
dc.identifier.issn | 1097-6825 | |
dc.identifier.uri | http://hdl.handle.net/10453/160198 | |
dc.description.abstract | BACKGROUND: Although a striking proportion (25% to 45%) of patients with chronic obstructive pulmonary disease are never-smokers, most genetic susceptibility studies have not focused on this group exclusively. OBJECTIVE: The aim of this study was to identify common genetic variants associated with FEV1 and its ratio to forced vital capacity (FVC) in never-smokers. METHODS: Genome-wide association studies were performed in 5070 never-smokers of the identification cohort LifeLines, and results (P < 10-5) were verified by using a meta-analysis of the Vlagtwedde-Vlaardingen study and the Rotterdam Study I-III (total n = 1966). Furthermore, we aimed to assess the effects of the replicated variants in more detail by performing genetic risk score, expression quantitative trait loci, and variant*ever-smoking interaction analyses. RESULTS: We identified associations between the FEV1/FVC ratio and 5 common genetic variants in the identification cohort, and 2 of these associations were replicated. The 2 variants annotated to the genes hedgehog interacting protein (HHIP) and family with sequence similarity 13 member A (FAM13A) were shown to have an additive effect on FEV1/FVC levels in the genetic risk score analysis; were associated with gene expression of HHIP and FAM13A in lung tissue, respectively; and were genome-wide significant in a meta-analysis including both identification and 4 verification cohorts (P < 2.19 × 10-7). Finally, we did not identify significant interactions between the variants and ever smoking. Results of the FEV1 identification analysis were not replicated. CONCLUSION: The genes HHIP and FAM13A confer a risk for airway obstruction in general that is not driven exclusively by cigarette smoking, which is the main risk factor for chronic obstructive pulmonary disease. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartof | Journal of Allergy and Clinical Immunology | |
dc.relation.isbasedon | 10.1016/j.jaci.2016.06.062 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 1107 Immunology | |
dc.subject.classification | Allergy | |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Carrier Proteins | |
dc.subject.mesh | Cohort Studies | |
dc.subject.mesh | Female | |
dc.subject.mesh | Forced Expiratory Volume | |
dc.subject.mesh | Genetic Predisposition to Disease | |
dc.subject.mesh | Genome-Wide Association Study | |
dc.subject.mesh | Genotype | |
dc.subject.mesh | GTPase-Activating Proteins | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Lung | |
dc.subject.mesh | Male | |
dc.subject.mesh | Membrane Glycoproteins | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Polymorphism, Single Nucleotide | |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive | |
dc.subject.mesh | Quantitative Trait Loci | |
dc.subject.mesh | Risk | |
dc.subject.mesh | Smoking | |
dc.subject.mesh | Spirometry | |
dc.subject.mesh | Vital Capacity | |
dc.subject.mesh | Young Adult | |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Carrier Proteins | |
dc.subject.mesh | Cohort Studies | |
dc.subject.mesh | Female | |
dc.subject.mesh | Forced Expiratory Volume | |
dc.subject.mesh | GTPase-Activating Proteins | |
dc.subject.mesh | Genetic Predisposition to Disease | |
dc.subject.mesh | Genome-Wide Association Study | |
dc.subject.mesh | Genotype | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Lung | |
dc.subject.mesh | Male | |
dc.subject.mesh | Membrane Glycoproteins | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Polymorphism, Single Nucleotide | |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive | |
dc.subject.mesh | Quantitative Trait Loci | |
dc.subject.mesh | Risk | |
dc.subject.mesh | Smoking | |
dc.subject.mesh | Spirometry | |
dc.subject.mesh | Vital Capacity | |
dc.subject.mesh | Young Adult | |
dc.subject.mesh | Lung | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive | |
dc.subject.mesh | Genetic Predisposition to Disease | |
dc.subject.mesh | GTPase-Activating Proteins | |
dc.subject.mesh | Carrier Proteins | |
dc.subject.mesh | Membrane Glycoproteins | |
dc.subject.mesh | Vital Capacity | |
dc.subject.mesh | Forced Expiratory Volume | |
dc.subject.mesh | Spirometry | |
dc.subject.mesh | Risk | |
dc.subject.mesh | Cohort Studies | |
dc.subject.mesh | Smoking | |
dc.subject.mesh | Genotype | |
dc.subject.mesh | Polymorphism, Single Nucleotide | |
dc.subject.mesh | Quantitative Trait Loci | |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Female | |
dc.subject.mesh | Male | |
dc.subject.mesh | Genome-Wide Association Study | |
dc.subject.mesh | Young Adult | |
dc.title | Genome-wide association study on the FEV1/FVC ratio in never-smokers identifies HHIP and FAM13A. | |
dc.type | Journal Article | |
utslib.citation.volume | 139 | |
utslib.location.activity | United States | |
utslib.for | 1107 Immunology | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Life Sciences | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | closed_access | * |
pubs.consider-herdc | false | |
dc.date.updated | 2022-08-15T04:22:09Z | |
pubs.issue | 2 | |
pubs.publication-status | Published | |
pubs.volume | 139 | |
utslib.citation.issue | 2 |
Abstract:
BACKGROUND: Although a striking proportion (25% to 45%) of patients with chronic obstructive pulmonary disease are never-smokers, most genetic susceptibility studies have not focused on this group exclusively. OBJECTIVE: The aim of this study was to identify common genetic variants associated with FEV1 and its ratio to forced vital capacity (FVC) in never-smokers. METHODS: Genome-wide association studies were performed in 5070 never-smokers of the identification cohort LifeLines, and results (P < 10-5) were verified by using a meta-analysis of the Vlagtwedde-Vlaardingen study and the Rotterdam Study I-III (total n = 1966). Furthermore, we aimed to assess the effects of the replicated variants in more detail by performing genetic risk score, expression quantitative trait loci, and variant*ever-smoking interaction analyses. RESULTS: We identified associations between the FEV1/FVC ratio and 5 common genetic variants in the identification cohort, and 2 of these associations were replicated. The 2 variants annotated to the genes hedgehog interacting protein (HHIP) and family with sequence similarity 13 member A (FAM13A) were shown to have an additive effect on FEV1/FVC levels in the genetic risk score analysis; were associated with gene expression of HHIP and FAM13A in lung tissue, respectively; and were genome-wide significant in a meta-analysis including both identification and 4 verification cohorts (P < 2.19 × 10-7). Finally, we did not identify significant interactions between the variants and ever smoking. Results of the FEV1 identification analysis were not replicated. CONCLUSION: The genes HHIP and FAM13A confer a risk for airway obstruction in general that is not driven exclusively by cigarette smoking, which is the main risk factor for chronic obstructive pulmonary disease.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph